GVHD,Acute Clinical Trial
Official title:
An Open Label, Multicenter, Phase I/II Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
The purpose of this study is to evaluate itacitinib in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).
This is an open label, single-arm, multicenter Phase I/II study of IBI377 in combination with corticosteroids as first-line treatment of subjects with Grade II to IV aGVHD. In Phase I, the PK, safety, tolerability and efficacy of IBI377 will be assessed in 12 subjects. In Phase II, the efficacy and safety will be assessed in 48 subjects. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05855707 -
Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis
|
Phase 1 | |
| Active, not recruiting |
NCT04522843 -
Analysis of Intestinal Defensin Expression in Acute GVHD
|
||
| Recruiting |
NCT05718791 -
CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
|
||
| Recruiting |
NCT05401955 -
Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD)
|
N/A | |
| Recruiting |
NCT05368181 -
MAP-guided Preemptive Therapy of aGvHD
|
Phase 2 | |
| Withdrawn |
NCT05443464 -
Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)
|
Phase 1 | |
| Not yet recruiting |
NCT06315309 -
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT04284904 -
Role of aGVHD Biomarkers on aGVHD Risks
|
||
| Not yet recruiting |
NCT06164288 -
Safety and Efficacy Study of hAESCs Therapy for aGVHD
|
Phase 1 |